Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Marker Therapeutics

Nasdaq:MRKR
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MRKR
Nasdaq
$86M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Marker Therapeutics has significant price volatility in the past 3 months.
MRKR Share Price and Events
7 Day Returns
12.8%
NasdaqGM:MRKR
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-72%
NasdaqGM:MRKR
1.6%
US Biotechs
-9.1%
US Market
MRKR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Marker Therapeutics (MRKR) 12.8% -23.2% -39.7% -72% -58.8% -26.6%
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • MRKR underperformed the Biotechs industry which returned 1.6% over the past year.
  • MRKR underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
MRKR
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Marker Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Marker Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Marker Therapeutics.

NasdaqGM:MRKR Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.9%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:MRKR
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.2
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.203 (1 + (1- 21%) (0.56%))
1.139
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.14
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.139 * 5.44%)
7.94%

Discounted Cash Flow Calculation for NasdaqGM:MRKR using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Marker Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:MRKR DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.94%)
2020 -16.19 Analyst x1 -15.00
2021 60.07 Analyst x1 51.56
2022 95.19 Est @ 58.47% 75.69
2023 134.64 Est @ 41.45% 99.19
2024 174.41 Est @ 29.54% 119.04
2025 211.38 Est @ 21.2% 133.67
2026 243.85 Est @ 15.36% 142.86
2027 271.34 Est @ 11.27% 147.27
2028 294.17 Est @ 8.41% 147.92
2029 313.03 Est @ 6.41% 145.83
Present value of next 10 years cash flows $1,048.00
NasdaqGM:MRKR DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $313.03 × (1 + 1.74%) ÷ (7.94% – 1.74%)
$5,138.45
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,138.45 ÷ (1 + 7.94%)10
$2,393.83
NasdaqGM:MRKR Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,048.00 + $2,393.83
$3,441.83
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $3,441.83 / 46.53
$73.97
NasdaqGM:MRKR Discount to Share Price
Calculation Result
Value per share (USD) From above. $73.97
Current discount Discount to share price of $1.85
= -1 x ($1.85 - $73.97) / $73.97
97.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Marker Therapeutics is available for.
Intrinsic value
>50%
Share price is $1.85 vs Future cash flow value of $73.97
Current Discount Checks
For Marker Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Marker Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Marker Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Marker Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Marker Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:MRKR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.47
NasdaqGM:MRKR Share Price ** NasdaqGM (2020-03-27) in USD $1.85
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Marker Therapeutics.

NasdaqGM:MRKR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:MRKR Share Price ÷ EPS (both in USD)

= 1.85 ÷ -0.47

-3.94x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Marker Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Marker Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Marker Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:MRKR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.94x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-17.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Marker Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Marker Therapeutics's assets?
Raw Data
NasdaqGM:MRKR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.96
NasdaqGM:MRKR Share Price * NasdaqGM (2020-03-27) in USD $1.85
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:MRKR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:MRKR Share Price ÷ Book Value per Share (both in USD)

= 1.85 ÷ 0.96

1.92x

* Primary Listing of Marker Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Marker Therapeutics is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Marker Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Marker Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Marker Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-17.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Marker Therapeutics expected to grow at an attractive rate?
  • Unable to compare Marker Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Marker Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Marker Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:MRKR Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:MRKR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -17.8%
NasdaqGM:MRKR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 55.4%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:MRKR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:MRKR Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 31 -66 2
2023-12-31 228 -34 4
2022-12-31 120 331 -36 4
2021-12-31 19 60 -33 5
2020-12-31 0 -16 -25 5
2020-03-28
NasdaqGM:MRKR Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 0 -18 -21
2019-09-30 0 -20 -152
2019-06-30 0 -18 -151
2019-03-31 0 -16 -150
2018-12-31 0 -14 -148
2018-09-30 0 -11 -15
2018-06-30 0 -9 -15
2018-03-31 0 -9 -12
2017-12-31 0 -8 -11
2017-09-30 0 -8 -10
2017-06-30 -8 -8
2017-03-31 -8 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Marker Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Marker Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:MRKR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Marker Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MRKR Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.96 -0.91 -1.00 2.00
2023-12-31 -0.51 0.05 -0.79 3.00
2022-12-31 -0.57 -0.51 -0.63 3.00
2021-12-31 -0.60 -0.45 -0.84 4.00
2020-12-31 -0.51 -0.37 -0.61 5.00
2020-03-28
NasdaqGM:MRKR Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.47
2019-09-30 -3.44
2019-06-30 -4.16
2019-03-31 -5.40
2018-12-31 -7.75
2018-09-30 -1.29
2018-06-30 -1.36
2018-03-31 -1.18
2017-12-31 -1.16
2017-09-30 -1.11
2017-06-30 -0.98
2017-03-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Marker Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Marker Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Marker Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Marker Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Marker Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Marker Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Marker Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Marker Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Marker Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Marker Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MRKR Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.21 -21.43 9.98
2019-09-30 0.00 -151.91 21.24
2019-06-30 0.00 -150.84 22.66
2019-03-31 0.21 -150.08 21.59 1.23
2018-12-31 0.21 -147.96 24.38
2018-09-30 0.21 -15.08 8.45 -3.82
2018-06-30 0.39 -14.68 7.04 -2.19
2018-03-31 0.18 -11.76 6.58 0.61
2017-12-31 0.18 -10.98 6.41
2017-09-30 0.18 -9.88 6.30 4.27
2017-06-30 -7.99 5.37 3.76
2017-03-31 -0.13 5.35 3.80
2016-12-31 -2.46 4.69 3.80
2016-09-30 -2.53 6.43 2.73
2016-06-30 28.08 5.04 3.13
2016-03-31 -38.12 4.80 2.09
2015-12-31 -34.07 4.45 1.71
2015-09-30 -33.15 1.86 2.44
2015-06-30 -62.85 2.85 0.95
2015-03-31 -1.88 2.44 0.78
2014-12-31 -30.88 3.18 0.19
2014-09-30 -33.62 3.63 0.56
2014-06-30 -33.17 2.68 0.55
2014-03-31 -34.80 2.48 0.59
2013-12-31 -5.53 1.97 0.70
2013-09-30 -4.11 1.90 0.84
2013-06-30 -4.13 2.15 0.88
2013-03-31 -6.01 4.61 1.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Marker Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Marker Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Marker Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Marker Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Marker Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Marker Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Marker Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Marker Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Marker Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Marker Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Marker Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Marker Therapeutics Company Filings, last reported 2 months ago.

NasdaqGM:MRKR Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 44.09 0.00 43.90
2019-09-30 47.88 0.00 48.48
2019-06-30 51.40 0.00 53.44
2019-03-31 55.61 0.00 57.71
2018-12-31 59.34 0.00 61.75
2018-09-30 0.69 0.01 4.29
2018-06-30 4.14 0.01 7.78
2018-03-31 0.62 0.01 2.80
2017-12-31 3.66 0.00 5.13
2017-09-30 5.94 0.01 7.61
2017-06-30 8.57 0.01 9.96
2017-03-31 4.14 0.01 5.93
2016-12-31 6.18 0.01 7.85
2016-09-30 7.49 0.01 9.59
2016-06-30 -19.33 0.03 3.77
2016-03-31 -25.70 0.03 5.72
2015-12-31 -21.36 0.05 6.58
2015-09-30 -27.39 0.05 6.09
2015-06-30 -68.10 0.05 3.11
2015-03-31 -8.71 0.05 1.45
2014-12-31 -1.02 0.05 0.14
2014-09-30 -0.66 0.05 0.61
2014-06-30 -2.56 0.44 0.02
2014-03-31 -5.51 0.52 0.09
2013-12-31 -8.77 3.85 0.05
2013-09-30 -5.10 2.64 0.00
2013-06-30 -4.77 2.54 0.05
2013-03-31 -5.49 2.35 0.00
  • Marker Therapeutics has no debt.
  • Marker Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Marker Therapeutics has sufficient cash runway for 2.4 years based on current free cash flow.
  • Unable to confirm if Marker Therapeutics has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Marker Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Marker Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Marker Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Marker Therapeutics dividends.
If you bought $2,000 of Marker Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Marker Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Marker Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:MRKR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:MRKR Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Marker Therapeutics has not reported any payouts.
  • Unable to verify if Marker Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Marker Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Marker Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Marker Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Marker Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Marker Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Marker Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Hoang
COMPENSATION $13,013,620
AGE 47
TENURE AS CEO 2.5 years
CEO Bio

Mr. Peter L. Hoang, MBA, has been the President and Chief Executive Officer of TapImmune, Inc. since September 22, 2017. Mr. Hoang has over 18 years of finance and deal making experience in investment banking and venture capital. He served as a Senior Vice President of Business Development and Strategy at Bellicum Pharmaceuticals, Inc. from November 2014 to March 17, 2017. From September 2012 to November 2014, he served as the Managing Director of Innovations in the Strategic Industry Ventures department at the University of Texas MD Anderson Cancer Center. Prior to MD Anderson, he served as a Managing Director of Mergers & Acquisitions in the healthcare investment banking practice for CIT Group from November 2010 to March 2012. Prior to CIT Group, he served as an Executive Director of the Global Mergers & Acquisitions Department at Oppenheimer & Co, Inc. He also served in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch and Deutsche Bank. He has been a Director of TapImmune, Inc. since September 22, 2017 and Esperance Pharmaceuticals Inc. since October 26, 2017. Mr. Hoang holds an M.B.A. from the Anderson School of Management at the University of California, Los Angeles, with Business Honors Society distinction and a B.A. from Yale University.

CEO Compensation
  • Peter's compensation has increased whilst company is loss making.
  • Peter's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Marker Therapeutics management team in years:

1.4
Average Tenure
45
Average Age
  • The average tenure for the Marker Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Peter Hoang

TITLE
President
COMPENSATION
$13M
AGE
47
TENURE
2.5 yrs

Tony Kim

TITLE
Chief Financial Officer
COMPENSATION
$3M
AGE
43
TENURE
1.3 yrs

Michael Loiacono

TITLE
Chief Accounting Officer
COMPENSATION
$3M
AGE
53
TENURE
3.6 yrs

Ann Leen

TITLE
Chief Scientific Officer
TENURE
1.4 yrs

Elizabeth Donnelly

TITLE
Director of Administration
TENURE
3.5 yrs

Shelia Sterr

TITLE
Director of Human Resources & Finance

Juan Vera

TITLE
Chief Development Officer & Director
AGE
39
TENURE
1.4 yrs

Mythili Koneru

TITLE
Chief Medical Officer
TENURE
1.1 yrs

Bob Florkiewicz

TITLE
Senior Director of Molecular Biology & Virology
Board of Directors Tenure

Average tenure and age of the Marker Therapeutics board of directors in years:

2
Average Tenure
58.5
Average Age
  • The average tenure for the Marker Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Rick Wasserman

TITLE
Independent Chairman
COMPENSATION
$83K
AGE
64
TENURE
1.4 yrs

Peter Hoang

TITLE
President
COMPENSATION
$13M
AGE
47
TENURE
2.5 yrs

Juan Vera

TITLE
Chief Development Officer & Director
AGE
39
TENURE
1.4 yrs

David Laskow-Pooley

TITLE
Independent Director
COMPENSATION
$83K
AGE
65
TENURE
5 yrs

John Wilson

TITLE
Independent Director
COMPENSATION
$112K
AGE
59
TENURE
1.4 yrs

Dave Eansor

TITLE
Independent Director
COMPENSATION
$112K
AGE
58
TENURE
1.4 yrs

Malcolm Brenner

TITLE
Member of Scientific Advisory Board
TENURE
2.2 yrs

Helen Heslop

TITLE
Member of Scientific Advisory Board
TENURE
2.2 yrs

Cliona Rooney

TITLE
Member of Scientific Advisory Board
TENURE
2.2 yrs

Jim Allison

TITLE
Member of Scientific Advisory Board
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
15. Aug 19 Buy Peter Hoang Individual 14. Aug 19 14. Aug 19 10,000 $4.62 $46,200
X
Management checks
We assess Marker Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Marker Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company’s MultiTAA T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial to treat breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. In addition, the company is developing PolyStart, a proprietary nucleic acid-based antigen expression technology to enhance the ability of the immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Details
Name: Marker Therapeutics, Inc.
MRKR
Exchange: NasdaqGM
Founded:
$86,085,165
46,532,522
Website: http://www.markertherapeutics.com
Address: Marker Therapeutics, Inc.
Phoenix Tower,
Suite 2240,
Houston,
Texas, 77027,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM MRKR Common Stock Nasdaq Global Market US USD 16. Jul 2002
DB GX1N Common Stock Deutsche Boerse AG DE EUR 16. Jul 2002
MUN GX1N Common Stock Boerse Muenchen DE EUR 16. Jul 2002
DB A2AR2W COM USD0.001(POST REV SPLIT) Deutsche Boerse AG DE EUR 28. Mar 2020
Number of employees
Current staff
Staff numbers
28
Marker Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 02:21
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/19
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.